Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221061 · ClinicalTrials.gov registry record · Early Phase 1
18F-FluorThanatrace (PET/CT) in Glioblastoma
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT04221061: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT04221061 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221061, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or after new treatment or surgery. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).
Interventions
- DRUG 18F-FluorThanatrace
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-20 |
| Est. Completion | 2024-06-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04221061
The ClinicalTrials.gov registry entry for NCT04221061 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-FluorThanatrace is the first listed.
NCT04221061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04221061 about?
NCT04221061 is a clinical study titled "18F-FluorThanatrace (PET/CT) in Glioblastoma". The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research study is being conducted to test ...
What is the current status of trial NCT04221061?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-20. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT04221061?
The interventions under investigation include: 18F-FluorThanatrace (DRUG).
Who is sponsoring clinical trial NCT04221061?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.